PFIZER INC PFE revenue by segment, product and geography
In its fiscal year ending 2025-12-31, PFIZER INC reported revenue across 1 business segments; the largest, Biopharma Segment, was $61.2B, 100.0% of the filed sum (-1.9% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Biopharma Segment$61.2B100.0%-1.9% yoy
Members sum to $61.2B against $62.6B consolidated (residual $1.38B) - eliminations or corporate lines the filer did not tag on this axis.
- Pfizer Centre One$1.34B97.0%+16.8% yoy
- Pfizer Ignite$41M3.0%-50.0% yoy
Members sum to $1.38B against $62.6B consolidated (residual $61.2B) - eliminations or corporate lines the filer did not tag on this axis.
- United States$37.1B59.2%-4.2% yoy
- International Developed Markets$16.2B25.9%+0.8% yoy
- International Emerging Markets$9.31B14.9%+4.9% yoy
Members sum to the consolidated $62.6B for this period.
- Biopharma Segment$14.2B100.0%+5.4% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.